Sage CEO’s M&A chatter sparks a spike, and an awkward correction
Few biotech CEOs like to hype data from tiny studies quite as much as an enthusiastic Jeff Jonas at Sage $SAGE. But on Thursday, he pumped it a little too hard.
Doni Bloomfield from Bloomberg taped him for a segment on the Bay State Biotech Report in which he talked about SAGE-217’s shot at becoming a “first-line” therapy for depression.
Not only did the drug cut scores on depression among severely depressed people by 20%, he said, “there’s a good likelihood it will help people sleep.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.